Splice-site mutations in KIF5A in the Japanese case series of amyotrophic lateral sclerosis.


Journal

Neurogenetics
ISSN: 1364-6753
Titre abrégé: Neurogenetics
Pays: United States
ID NLM: 9709714

Informations de publication

Date de publication:
03 2021
Historique:
received: 06 06 2020
accepted: 12 08 2020
pubmed: 21 8 2020
medline: 19 11 2021
entrez: 21 8 2020
Statut: ppublish

Résumé

Our objective was to investigate the frequency of KIF5A variants in amyotrophic lateral sclerosis (ALS) and the clinical characteristics of familial ALS (FALS) associated with variants in KIF5A. Whole-exome sequence analysis was performed for a Japanese series of 43 families with FALS and 444 patients with sporadic ALS (SALS), in whom causative variants had not been identified. We compared the frequencies of rare variants (MAF < 0.01) in KIF5A, including missense and loss of function (LoF) variants, between ALS and control subjects (n = 1163). Clinical characteristics of patients with FALS carrying pathogenic variants in KIF5A were also described. LoF variants were identified only in the probands of two families with FALS, both of which were 3' splice-site variants leading to exon skipping and an altered C-terminal domain, located in the mutational hotspot causing FALS, and were considered to be pathogenic for FALS. Rare missense variants in KIF5A were identified in five patients with SALS (1.13%) and 11 control subjects (0.95%, carrier frequency), which were not significantly different. Consequently, the pathogenic LoF variants in KIF5A accounted for 2.1% of all FALS families in this study. These patients suffered from ALS characteristically associated with the predominant involvement of upper motor neuron. In conclusion, we identified two pathogenic splice-site variants in KIF5A in the probands in two Japanese families with FALS, which altered the C-terminal region of KIF5A. Our findings broaden the phenotype spectrum of ALS associated with variants in KIF5A in the Japanese series.

Identifiants

pubmed: 32815063
doi: 10.1007/s10048-020-00626-1
pii: 10.1007/s10048-020-00626-1
doi:

Substances chimiques

KIF5A protein, human 0
Kinesins EC 3.6.4.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-17

Références

Taylor JP, Brown RH Jr, Cleveland DW (2016) Decoding ALS: from genes to mechanism. Nature 539(7628):197–206. https://doi.org/10.1038/nature20413
doi: 10.1038/nature20413 pubmed: 5585017 pmcid: 5585017
Leblond CS, Kaneb HM, Dion PA, Rouleau GA (2014) Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol 262 Pt B:91–101. https://doi.org/10.1016/j.expneurol.2014.04.013
doi: 10.1016/j.expneurol.2014.04.013 pubmed: 24780888
White MA, Sreedharan J (2016) Amyotrophic lateral sclerosis: recent genetic highlights. Curr Opin Neurol 29(5):557–564. https://doi.org/10.1097/WCO.0000000000000367
doi: 10.1097/WCO.0000000000000367 pubmed: 27538057
Naruse H, Ishiura H, Mitsui J, Date H, Takahashi Y, Matsukawa T, Tanaka M, Ishii A, Tamaoka A, Hokkoku K, Sonoo M, Segawa M, Ugawa Y, Doi K, Yoshimura J, Morishita S, Goto J, Tsuji S (2018) Molecular epidemiological study of familial amyotrophic lateral sclerosis in Japanese population by whole-exome sequencing and identification of novel HNRNPA1 mutation. Neurobiol Aging 61:255.e259–255.e216. https://doi.org/10.1016/j.neurobiolaging.2017.08.030
doi: 10.1016/j.neurobiolaging.2017.08.030
Naruse H, Ishiura H, Mitsui J, Takahashi Y, Matsukawa T, Tanaka M, Doi K, Yoshimura J, Morishita S, Goto J, Toda T, Tsuji S (2019) Burden of rare variants in causative genes for amyotrophic lateral sclerosis (ALS) accelerates age at onset of ALS. J Neurol Neurosurg Psychiatry 90(5):537–542. https://doi.org/10.1136/jnnp-2018-318568
doi: 10.1136/jnnp-2018-318568 pubmed: 30355605
Takahashi Y, Seki N, Ishiura H, Mitsui J, Matsukawa T, Kishino A, Onodera O, Aoki M, Shimozawa N, Murayama S, Itoyama Y, Suzuki Y, Sobue G, Nishizawa M, Goto J, Tsuji S (2008) Development of a high-throughput microarray-based resequencing system for neurological disorders and its application to molecular genetics of amyotrophic lateral sclerosis. Arch Neurol 65(10):1326–1332. https://doi.org/10.1001/archneur.65.10.1326
doi: 10.1001/archneur.65.10.1326 pubmed: 18852346
Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, Belzil VV, Dion PA, Higasa K, Doi K, Ishiura H, Mitsui J, Date H, Ahsan B, Matsukawa T, Ichikawa Y, Moritoyo T, Ikoma M, Hashimoto T, Kimura F, Murayama S, Onodera O, Nishizawa M, Yoshida M, Atsuta N, Sobue G, JaCals FJA, Williams KL, Blair IP, Nicholson GA, Gonzalez-Perez P, Brown RH Jr, Nomoto M, Elenius K, Rouleau GA, Fujiyama A, Morishita S, Goto J, Tsuji S (2013) ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet 93(5):900–905. https://doi.org/10.1016/j.ajhg.2013.09.008
doi: 10.1016/j.ajhg.2013.09.008 pubmed: 24119685 pmcid: 3824132
Naruse H, Iwata A, Takahashi Y, Ichihara K, Kamei S, Yamatoku M, Hirayama T, Suzuki N, Aoki M, Miyagawa T, Shimizu J, Tsuji S, Goto J (2013) Familial amyotrophic lateral sclerosis with novel A4D SOD1 mutation with late age at onset and rapid progressive course. Neurol Clin Neurosci 1(1):45–47. https://doi.org/10.1002/ncn3.8
Segawa M, Hoshi A, Naruse H, Kuroda M, Bujo H, Ugawa Y (2015) A patient with familial amyotrophic lateral sclerosis associated with a new valosin-containing protein (VCP) gene mutation. Rinsho Shinkeigaku 55(12):914–920. https://doi.org/10.5692/clinicalneurol.cn-000765
doi: 10.5692/clinicalneurol.cn-000765 pubmed: 26511028
Ishiura H, Takahashi Y, Mitsui J, Yoshida S, Kihira T, Kokubo Y, Kuzuhara S, Ranum LP, Tamaoki T, Ichikawa Y, Date H, Goto J, Tsuji S (2012) C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. Arch Neurol 69(9):1154–1158. https://doi.org/10.1001/archneurol.2012.1219
doi: 10.1001/archneurol.2012.1219 pubmed: 22637429
Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Holtta-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chio A, Restagno G, Borghero G, Sabatelli M, Consortium I, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72(2):257–268. https://doi.org/10.1016/j.neuron.2011.09.010
doi: 10.1016/j.neuron.2011.09.010 pubmed: 3200438 pmcid: 3200438
Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, Rubinsztein DC, Marchuk DA (2002) A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 71(5):1189–1194. https://doi.org/10.1086/344210
doi: 10.1086/344210 pubmed: 12355402 pmcid: 385095
Liu YT, Laura M, Hersheson J, Horga A, Jaunmuktane Z, Brandner S, Pittman A, Hughes D, Polke JM, Sweeney MG, Proukakis C, Janssen JC, Auer-Grumbach M, Zuchner S, Shields KG, Reilly MM, Houlden H (2014) Extended phenotypic spectrum of KIF5A mutations: from spastic paraplegia to axonal neuropathy. Neurology 83(7):612–619. https://doi.org/10.1212/wnl.0000000000000691
doi: 10.1212/wnl.0000000000000691 pubmed: 25008398 pmcid: 4141994
Kaji S, Kawarai T, Miyamoto R, Nodera H, Pedace L, Orlacchio A, Izumi Y, Takahashi R, Kaji R (2016) Late-onset spastic paraplegia type 10 (SPG10) family presenting with bulbar symptoms and fasciculations mimicking amyotrophic lateral sclerosis. J Neurol Sci 364:45–49. https://doi.org/10.1016/j.jns.2016.03.001
doi: 10.1016/j.jns.2016.03.001 pubmed: 27084214
Duis J, Dean S, Applegate C, Harper A, Xiao R, He W, Dollar JD, Sun LR, Waberski MB, Crawford TO, Hamosh A, Stafstrom CE (2016) KIF5A mutations cause an infantile onset phenotype including severe myoclonus with evidence of mitochondrial dysfunction. Ann Neurol 80(4):633–637. https://doi.org/10.1002/ana.24744
doi: 10.1002/ana.24744 pubmed: 27463701 pmcid: 5042851
Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt J, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya SBN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D’Alfonso S, Corrado L, Capasso M, Ferrucci L, Moreno CAM, Kamalakaran S, Goldstein DB, Gitler AD, Harris T, Myers RM, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Soraru G, Cereda C, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek A, Munoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Perez J, Garcia-Redondo A, Al-Chalabi A, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chio A, Shaw CE, Traynor BJ, Landers JE (2018) Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97(6):1268–1283.e1266. https://doi.org/10.1016/j.neuron.2018.02.027
doi: 10.1016/j.neuron.2018.02.027 pubmed: 29566793 pmcid: 5867896
Brenner D, Yilmaz R, Müller K, Grehl T, Petri S, Meyer T, Grosskreutz J, Weydt P, Ruf W, Neuwirth C, Weber M, Pinto S, Claeys KG, Schrank B, Jordan B, Knehr A, Günther K, Hübers A, Zeller D, Kubisch C, Jablonka S, Sendtner M, Klopstock T, de Carvalho M, Sperfeld A, Borck G, Volk AE, Dorst J, Weis J, Otto M, Schuster J, Del Tredici K, Braak H, Danzer KM, Freischmidt A, Meitinger T, Strom TM, Ludolph AC, Andersen PM, Weishaupt JH (2018) Hot-spot KIF5A mutations cause familial ALS. Brain 141(3):688–697. https://doi.org/10.1093/brain/awx370
doi: 10.1093/brain/awx370 pubmed: 29342275 pmcid: 5837483
Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299
doi: 10.1080/146608200300079536
Krawczak M, Thomas NS, Hundrieser B, Mort M, Wittig M, Hampe J, Cooper DN (2007) Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Hum Mutat 28(2):150–158. https://doi.org/10.1002/humu.20400
doi: 10.1002/humu.20400 pubmed: 17001642
Crimella C, Baschirotto C, Arnoldi A, Tonelli A, Tenderini E, Airoldi G, Martinuzzi A, Trabacca A, Losito L, Scarlato M, Benedetti S, Scarpini E, Spinicci G, Bresolin N, Bassi MT (2012) Mutations in the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in axonal Charcot-Marie-Tooth type 2. Clin Genet 82(2):157–164. https://doi.org/10.1111/j.1399-0004.2011.01717.x
doi: 10.1111/j.1399-0004.2011.01717.x pubmed: 21623771
Jennings S, Chenevert M, Liu L, Mottamal M, Wojcik EJ, Huckaba TM (2017) Characterization of kinesin switch I mutations that cause hereditary spastic paraplegia. PLoS One 12(7):e0180353. https://doi.org/10.1371/journal.pone.0180353
doi: 10.1371/journal.pone.0180353 pubmed: 28678816 pmcid: 5498027
Faruq M, Kumar D, Wadhwa S, Shamim U, Mathur A, Parveen S, Garg A, Srivastava AK (2019) Intrafamilial variable spastic paraplegia/ataxia/ALS phenotype linked to a novel KIF5A mutation. Clin Genet 96(3):271–273. https://doi.org/10.1111/cge.13585
doi: 10.1111/cge.13585 pubmed: 31286494
Campbell PD, Shen K, Sapio MR, Glenn TD, Talbot WS, Marlow FL (2014) Unique function of Kinesin Kif5A in localization of mitochondria in axons. J Neurosci 34(44):14717–14732. https://doi.org/10.1523/jneurosci.2770-14.2014
doi: 10.1523/jneurosci.2770-14.2014 pubmed: 25355224 pmcid: 4212069
Hares K, Redondo J, Kemp K, Rice C, Scolding N, Wilkins A (2017) Axonal motor protein KIF5A and associated cargo deficits in multiple sclerosis lesional and normal-appearing white matter. Neuropathol Appl Neurobiol 43(3):227–241. https://doi.org/10.1111/nan.12305
doi: 10.1111/nan.12305 pubmed: 26785938

Auteurs

Hiroya Naruse (H)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hiroyuki Ishiura (H)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Jun Mitsui (J)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8655, Japan.

Yuji Takahashi (Y)

Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.

Takashi Matsukawa (T)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8655, Japan.

Kaori Sakuishi (K)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kiyotaka Nakamagoe (K)

Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Zenshi Miyake (Z)

Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Akira Tamaoka (A)

Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Jun Goto (J)

Department of Neurology, International University of Health and Welfare Mita Hospital, Tokyo, Japan.

Jun Yoshimura (J)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.

Koichiro Doi (K)

School of Bioscience and Biotechnology, Tokyo University of Technology, Tokyo, Japan.

Shinichi Morishita (S)

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.

Tatsushi Toda (T)

Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Shoji Tsuji (S)

Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8655, Japan. tsuji@m.u-tokyo.ac.jp.
Institute of Medical Genomics, International University of Health and Welfare, Chiba, Japan. tsuji@m.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH